PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value ...
Arrowhead CEO and CCO responded to the backlash against the pricing of the Helldivers 2 X Killzone 2 cosmetic, apologizing for the steep price and looking for feedback. Helldivers 2 has received its ...
Since Helldivers 2 developer Arrowhead deployed the opening bit of the game's first ever crossover - with PlayStation shooter Killzone - yesterday, the prices players are being asked to pay for this ...
B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 report. The firm says Ionis Pharmaceuticals’ (IONS) Tryngolza ...
Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s fiscal Q4 update centered primarily on the large ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, ...
The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, the Pasadena company reached its lowest close of ...
Piper Sandler lowered the firm’s price target on Arrowhead (ARWR) to $45 from $62 and keeps an Overweight rating on the shares. The firm notes Arrowhead entered a strategic partnership with Sarepta ...
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $100 from $70 and keeps an Overweight rating on the shares. The firm notes Arrowhead has launched Redemplo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results